Identifying Barriers to Initiation of Sodium-Glucose Cotransporter-2 Inhibitor Therapy in Patients Hospitalized With Heart Failure With Reduced Ejection Fraction

Identifying Barriers to Initiation of Sodium-Glucose Cotransporter-2 Inhibitor Therapy in Patients Hospitalized With Heart Failure With Reduced Ejection Fraction—Reply

Published:2023-12-01 Issue:12 Volume:8 Page:1188
ISSN:2380-6583
Container-title:JAMA Cardiology
language:en
Short-container-title:JAMA Cardiol

Author:

Pierce Jacob B.¹,Fonarow Gregg C.²³,Greene Stephen J.⁴⁵

Affiliation:

1. Department of Medicine, Duke University Medical Center, Durham, North Carolina

2. Ahmanson-UCLA Cardiomyopathy Center, University of California, Los Angeles

3. Associate Editor for Health Care Quality and Guidelines, JAMA Cardiology

4. Division of Cardiology, Duke University Medical Center, Durham, North Carolina

5. Duke Clinical Research Institute, Durham, North Carolina

Publisher

American Medical Association (AMA)

Subject

Cardiology and Cardiovascular Medicine

Link

https://jamanetwork.com/journals/jamacardiology/articlepdf/2810728/jamacardiology_pierce_2023_lr_230011_1702400230.80648.pdf

Reference6 articles.

1. Contemporary use of sodium-glucose cotransporter-2 inhibitor therapy among patients hospitalized for heart failure with reduced ejection fraction in the US: the Get With The Guidelines–Heart Failure Registry.;Pierce;JAMA Cardiol,2023

2. Kidney function and outcomes in patients hospitalized with heart failure.;Patel;J Am Coll Cardiol,2021

3. Clinical inertia and medical therapy for heart failure: the unintended harms of ‘first, do no harm.’;Greene;Eur J Heart Fail,2021

4. Quality of care and outcomes among patients hospitalized for heart failure in rural vs urban US hospitals: the Get With The Guidelines–Heart Failure Registry.;Pierce;JAMA Cardiol,2023

5. Sex, permanent drug discontinuation, and study retention in clinical trials: insights from the TIMI trials.;Lau;Circulation,2021